Phase 3 randomized, controlled DISCOVER study of daily emtricitabine/tenofovir alafenamide (F/TAF) or emtricitabine/tenofovir disoproxil fumarate (F/TDF) for HIV pre-exposure prophylaxis (PrEP): week 96 results

被引：0
|
作者：
Ruane, P. J. [1 ]
Clarke, A. [2 ]
Post, F. A. [3 ]
Schembri, G. [4 ]
Jessen, H. [5 ]
Trottier, B. [6 ]
Bergin, C. [7 ]
Molina, J-M [8 ]
Wong, P. [9 ]
Ebrahimi, R. [9 ]
Brainard, D. M. [9 ]
Osinusi, A. [9 ]
Das, M. [9 ]
McCallister, S. [9 ]
机构：
[1] Ruane Med & Liver Hlth Inst, Beverly Hills, CA USA
[2] Brighton & Sussex Univ Hosp NHS Trust, Brighton, E Sussex, England
[3] Kings Coll Hosp NHS Fdn Trust, London, England
[4] Cent Manchester Univ Hosp, Manchester, Lancs, England
[5] Praxis Jessen2 Kollegen, Berlin, Germany
[6] Clin Med Urbaine Quartier Latin, Montreal, PQ, Canada
[7] St James Hosp, Dublin, Ireland
[8] Univ Paris Diderot, Paris, France
[9] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA
来源：
HIV MEDICINE | 2019年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
PE3/16
引用
收藏
页码：95 / 96
页数：2
相关论文
共 50 条
  • [1] Longer term safety of emtricitabine/tenofovir alafenamide (F/TAF) and emtricitabine/tenofovir disoproxil fumarate (F/TDF) for HIV pre-exposure prophylaxis (PrEP): DISCOVER trial week 96 results
    Ogbuagu, O.
    Podzamczer, D.
    Salazar, L.
    Henry, K.
    Asmuth, D.
    Wohl, D.
    Gilson, R.
    Shao, Y.
    Ebrahimi, R.
    Carter, C.
    Das, M.
    McCallister, S.
    Brunetta, J.
    Kronborg, G.
    Reeves, I.
    Spinner, C.
    [J]. HIV MEDICINE, 2020, 21 : 12 - 12
  • [2] DISCOVER in Europe: a sub-analysis of the phase 3 randomized, controlled trial of daily emtricitabine/tenofovir alafenamide (F/TAF) or emtricitabine/tenofovir disoproxil fumarate (F/TDF) for HIV pre-exposure prophylaxis (PrEP)
    Post, F.
    Spinner, C.
    Coll, P.
    Hawkins, T.
    Anderson, J.
    Zhong, L.
    McCallister, S.
    [J]. HIV MEDICINE, 2019, 20 : 243 - 244
  • [3] Switching to a single-tablet regimen bictegravir, emtricitabine, and tenofovir alafenamide (B/F/TAF) from dolutegravir (DTG) plus emtricitabine and either tenofovir alafenamide or tenofovir disoproxil fumarate (F/TAF or F/TDF)
    Sax, P. E.
    Rockstroh, J.
    Luetkemeyer, A.
    Yasdanpanah, Y.
    Ward, D.
    Trottier, B.
    Rieger, A.
    Liu, H.
    Acosta, R.
    Collins, S. E.
    Brainard, D.
    Martin, H.
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2019, 22 : 3 - 4
  • [4] Eligibility of patients in a community HIV setting for switching rilpivirine/emtricitabine/tenofovir disoproxil fumarate (R/F/TDF) to tenofovir alafenamide(TAF)
    Goorney, B.
    Perez, K.
    [J]. HIV MEDICINE, 2019, 20 : 39 - 39
  • [5] Why Are Patients Switching from Tenofovir Disoproxil Fumarate/Emtricitabine (Truvada) to Tenofovir Alafenamide/Emtricitabine (Descovy) for Pre-Exposure Prophylaxis?
    D'Angelo, Alexa B.
    Westmoreland, Drew A.
    Carneiro, Pedro B.
    Johnson, Jeremiah
    Grov, Christian
    [J]. AIDS PATIENT CARE AND STDS, 2021, 35 (08) : 327 - 334
  • [6] Week 48 results of a Phase 3 randomized controlled trial of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) vs dolutegravir plus emtricitabine/tenofovir Disoproxil Fumarate (DTG plus F/TDF) as initial treatment in HIV/HBV-coinfected adults (ALLIANCE)
    Avihingsanon, A.
    Lu, H.
    Leong, C. L.
    Hung, C. -C.
    Koenig, E.
    Kiertiburanakul, S.
    Lee, M. -P.
    Supparatpinyo, K.
    Zhang, F.
    Rahman, S.
    Brogan, M. D'Antoni
    Wang, H.
    Hindman, J.
    Martin, H.
    Baeten, J.
    Li, T.
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 : 226 - 227
  • [7] WEEK 48 RESULTS OF A PHASE 3 RANDOMIZED CONTROLLED TRIAL OF BICTEGRAVIR/EMTRICITABINE/TENOFOVIR ALAFENAMIDE (B/F/TAF) VS DOLUTEGRAVIR plus EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE (DTG plus F/TDF) IN ART-NAIVE, HIV/HBV-COINFECTED ADULTS (ALLIANCE)
    Avihingsanon, Anchalee
    Lu, Hongzhou
    Leong, Chee Loon
    Hung, Chien-Ching
    Koenig, Ellen
    Kiertiburanakul, Sasisopin
    Lee, Man-Po
    Supparatpinyo, Khuanchai
    Rahman, Sophia
    Brogan, Michelle D'Antoni
    Wang, Hongyuan
    Hindman, Jason
    Martin, Hal
    Mehta, Swarup S.
    Baeten, Jared
    Zhang, Fujie
    [J]. GASTROENTEROLOGY, 2023, 164 (06) : S1241 - S1241
  • [8] Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial
    Mayer, Kenneth H.
    Molina, Jean-Michel
    Thompson, Melanie A.
    Anderson, Peter L.
    Mounzer, Karam C.
    De Wet, Joss J.
    DeJesus, Edwin
    Jessen, Heiko
    Grant, Robert M.
    Ruane, Peter J.
    Wong, Pamela
    Ebrahimi, Ramin
    Zhong, Lijie
    Mathias, Anita
    Callebaut, Christian
    Collins, Sean E.
    Das, Moupali
    McCallister, Scott
    Brainard, Diana M.
    Brinson, Cynthia
    Clarke, Amanda
    Coll, Pep
    Post, Frank A.
    Hare, C. Bradley
    [J]. LANCET, 2020, 396 (10246): : 239 - 254
  • [9] Comparing effectiveness and tolerability of emtricitabine/tenofovir alafenamide (F/TAF) with emtricitabine/tenofovir disoproxil fumarate (F/TDF) in HIV-1 infected adult patients in routine clinical practice: a cross cohort analysis
    Esser, S.
    Stellbrink, H-J
    Heiken, H.
    Meynard, J-L
    Thorpe, D.
    Schreiber, S.
    Heinzkill, M.
    Sahali, S.
    Ramroth, H.
    Haubrich, R.
    [J]. HIV MEDICINE, 2019, 20 : 67 - 68
  • [10] Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, 3 trial
    Ogbuagu, Onyema
    Ruane, Peter J.
    Podzamczer, Daniel
    Salazar, Laura C.
    Henry, Keith
    Asmuth, David M.
    Wohl, David
    Gilson, Richard
    Shao, Yongwu
    Ebrahimi, Ramin
    Cox, Stephanie
    Kintu, Alexander
    Carter, Christoph
    Das, Moupali
    Baeten, Jared M.
    Brainard, Diana M.
    Whitlock, Gary
    Brunetta, Jason M.
    Kronborg, Gitte
    Spinner, Christoph D.
    [J]. LANCET HIV, 2021, 8 (07): : E397 - E407
12345